EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+59.14%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$605M
AUM Growth
+$605M
(+59%)
Cap. Flow
+$75.6M
Cap. Flow
% of AUM
12.49%
Top 10 Holdings %
Top 10 Hldgs %
55.57%
Holding
81
New
22
Increased
20
Reduced
20
Closed
14
Top Buys
Top Sells
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$31M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
$27.2M |
| 3 |
Danaher
DHR
|
$22.3M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$15.6M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$12.8M |
Sector Composition
| 1 | Healthcare | 96.24% |
| 2 | Communication Services | 1.96% |
| 3 | Financials | 0% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $53.1M | 7.28% | +954,738 | New | +$53.1M |
|
2
TG Therapeutics
TGTX
$4.65B
| $48.7M | 6.68% | 2,501,272 +40,135 | +2% | +$782K |
|
|
AMRN
3
Amarin Corp
AMRN
$311M
| $33.1M | 4.54% | 4,786,101 +1,282,039 | +37% | +$8.87M |
|
|
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $32.8M | 4.49% | 448,264 +341,879 | +321% | +$25M |
|
5
Ascendis Pharma
ASND
$11.8B
| $32.6M | 4.47% | 220,344 -55,150 | -20% | -$8.16M |
|
6
AstraZeneca
AZN
$248B
| $29.7M | 4.08% | 562,151 +209,600 | +59% | +$11.1M |
|
7
United Therapeutics
UTHR
$13.8B
| $28.2M | 3.86% | +232,676 | New | +$28.2M |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $27.2M | 3.73% | 1,007,083 -1,006,384 | -50% | -$27.2M |
|
|
HSKA
9
DELISTED
Heska Corp
HSKA
| $26.1M | 3.58% | 280,256 +259,485 | +1,249% | +$24.2M |
|
|
DCPH
10
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $25M | 3.43% | 418,652 +4,571 | +1% | +$273K |
|
|
11
BioCryst Pharmaceuticals
BCRX
$1.74B
| $23.1M | 3.17% | 4,847,792 -2,694,580 | -36% | -$12.8M |
|
|
12
Danaher
DHR
$147B
| $19.1M | 2.62% | 107,857 -126,100 | -54% | -$22.3M |
|
13
Fate Therapeutics
FATE
$120M
| $18.2M | 2.5% | 531,258 +225,773 | +74% | +$7.75M |
|
14
The Ensign Group
ENSG
$9.91B
| $17.9M | 2.46% | 427,307 +70,279 | +20% | +$2.94M |
|
|
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
| $15.7M | 2.15% | +760,551 | New | +$15.7M |
|
|
16
Apellis Pharmaceuticals
APLS
$3.48B
| $13.7M | 1.89% | 420,932 -478,542 | -53% | -$15.6M |
|
|
MODN
17
DELISTED
MODEL N, INC.
MODN
| $11.8M | 1.62% | 340,764 -33,520 | -9% | -$1.17M |
|
18
Sarepta Therapeutics
SRPT
$1.78B
| $11.5M | 1.58% | +71,731 | New | +$11.5M |
|
19
GSK
GSK
$79.9B
| $9.27M | 1.27% | 227,263 -283,308 | -55% | -$11.6M |
|
20
Celldex Therapeutics
CLDX
$1.47B
| $9.27M | 1.27% | +712,698 | New | +$9.27M |
|
21
Aurinia Pharmaceuticals
AUPH
$1.58B
| $8.91M | 1.22% | +548,325 | New | +$8.91M |
|
22
Liquidia Corp
LQDA
$2.38B
| $7.24M | 0.99% | 859,724 +615,087 | +251% | +$5.18M |
|
|
TARO
23
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $6.99M | 0.96% | 105,169 +28,710 | +38% | +$1.91M |
|
24
Pacira BioSciences
PCRX
$1.2B
| $6.96M | 0.95% | +132,655 | New | +$6.96M |
|
|
MYOK
25
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $6.82M | 0.94% | 70,594 +42,842 | +154% | +$4.14M |
|